 | • レポートコード：MMG23DC14396 • 出版社/出版日：Market Monitor Global / 2023年12月 • レポート形態：英語、PDF、118ページ • 納品方法：Eメール（受注後2-3営業日） • 産業分類：医薬品 |
| Single User（1名様閲覧用） | ￥487,500 (USD3,250) | ▷ お問い合わせ |
| Multi User（20名様閲覧用） | ￥633,750 (USD4,225) | ▷ お問い合わせ |
| Enterprise User（閲覧人数制限なし） | ￥731,250 (USD4,875) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 当調査レポートは次の情報を含め、世界のリポソームナノキャリア薬剤市場規模と予測を収録しています。・世界のリポソームナノキャリア薬剤市場：売上、2018年-2023年、2024年-2029年 ・世界のリポソームナノキャリア薬剤市場：販売量、2018年-2023年、2024年-2029年 ・世界のトップ5企業、2022年 世界のリポソームナノキャリア薬剤市場は2022年に000Mドルと評価され、予測期間中に000％のCAGRで2029年までに000Mドルに達すると予測されています。米国市場は2022年に000Mドルと推定されており、中国は2029年までに000Mドルに達すると予測されています。「リポソーム医薬品」セグメントは今後6年間、000%のCAGRで2029年までに000Mドルに成長すると予測されています。 リポソームナノキャリア薬剤のグローバル主要企業は、Johnson & Johnson、 Sun Pharmaceutical、 CSPC、 Kinyond、 Teva、 Fudan-Zhangjiang、 Zydus Cadila、 TTY Biopharma、 Pacira、 Luye Pharma、 Leadiant Biosciences、 Ipsen、 Sayre Therapeutics、 Jazz、 Alnylam、 Bausch Health、 Acrotech Biopharma、 Takeda、 Chiesi Farmaceutici、 Gilead Sciencesなどです。2022年にトップ5企業がグローバル売上シェアの約000%を占めています。 MARKET MONITOR GLOBAL（MMG）は、リポソームナノキャリア薬剤のメーカー、サプライヤー、流通業者、および業界の専門家を調査しました。これには、販売量、売上、需要、価格変動、製品タイプ、最近の動向と計画、産業トレンド、成長要因、課題、阻害要因、潜在的なリスクなどが含まれます。 【セグメント別市場分析】 世界のリポソームナノキャリア薬剤市場：タイプ別、2018年-2023年、2024年-2029年 世界のリポソームナノキャリア薬剤市場：タイプ別市場シェア、2022年 ・リポソーム医薬品、脂質ナノ粒子医薬品 世界のリポソームナノキャリア薬剤市場：用途別、2018年-2023年、2024年-2029年 世界のリポソームナノキャリア薬剤市場：用途別市場シェア、2022年 ・病院、薬局、その他 世界のリポソームナノキャリア薬剤市場：地域・国別、2018年-2023年、2024年-2029年 世界のリポソームナノキャリア薬剤市場：地域別市場シェア、2022年 ・北米：アメリカ、カナダ、メキシコ ・ヨーロッパ：ドイツ、フランス、イギリス、イタリア、ロシア ・アジア：中国、日本、韓国、東南アジア、インド ・南米：ブラジル、アルゼンチン ・中東・アフリカ：トルコ、イスラエル、サウジアラビア、UAE 【競合分析】 また、当レポートは主要な市場参加者の分析を提供します。 ・主要企業におけるリポソームナノキャリア薬剤のグローバル売上、2018年-2023年 ・主要企業におけるリポソームナノキャリア薬剤のグローバル売上シェア、2022年 ・主要企業におけるリポソームナノキャリア薬剤のグローバル販売量、2018年-2023年 ・主要企業におけるリポソームナノキャリア薬剤のグローバル販売量シェア、2022年 さらに、当レポートは主要企業のプロファイルを提示します。 Johnson & Johnson、 Sun Pharmaceutical、 CSPC、 Kinyond、 Teva、 Fudan-Zhangjiang、 Zydus Cadila、 TTY Biopharma、 Pacira、 Luye Pharma、 Leadiant Biosciences、 Ipsen、 Sayre Therapeutics、 Jazz、 Alnylam、 Bausch Health、 Acrotech Biopharma、 Takeda、 Chiesi Farmaceutici、 Gilead Sciences ************************************************************* ・調査・分析レポートの概要 リポソームナノキャリア薬剤市場の定義 市場セグメント 世界のリポソームナノキャリア薬剤市場概要 当レポートの特徴・ベネフィット 調査手法と情報源 ・世界のリポソームナノキャリア薬剤市場規模 世界のリポソームナノキャリア薬剤市場規模：2022年 VS 2029年 世界のリポソームナノキャリア薬剤市場規模と予測 2018年-2029年 ・競争状況 グローバルトップ企業 売上ベースでのグローバルトップ企業 企業別グローバルでのリポソームナノキャリア薬剤の売上 グローバルトップ3およびトップ5企業、2022年売上ベース グローバル企業のリポソームナノキャリア薬剤製品タイプ グローバルにおけるティア1、ティア2、ティア3企業 ・タイプ別市場分析 タイプ区分：リポソーム医薬品、脂質ナノ粒子医薬品 リポソームナノキャリア薬剤のタイプ別グローバル売上・予測 ・用途別市場分析 用途区分：病院、薬局、その他 リポソームナノキャリア薬剤の用途別グローバル売上・予測 ・地域別市場分析 地域別リポソームナノキャリア薬剤市場規模 2022年と2029年 地域別リポソームナノキャリア薬剤売上・予測 北米市場：アメリカ、カナダ、メキシコ ヨーロッパ市場：ドイツ、フランス、イギリス、イタリア、ロシア アジア市場：中国、日本、韓国、東南アジア、インド 南米市場：ブラジル、アルゼンチン 中東・アフリカ市場：トルコ、イスラエル、サウジアラビア、UAE ・主要企業のプロファイル（企業概要、事業概要、主要製品、売上、ニュースなど） Johnson & Johnson、 Sun Pharmaceutical、 CSPC、 Kinyond、 Teva、 Fudan-Zhangjiang、 Zydus Cadila、 TTY Biopharma、 Pacira、 Luye Pharma、 Leadiant Biosciences、 Ipsen、 Sayre Therapeutics、 Jazz、 Alnylam、 Bausch Health、 Acrotech Biopharma、 Takeda、 Chiesi Farmaceutici、 Gilead Sciences ... |
This research report provides a comprehensive analysis of the Liposomes Nanocarrier Drug market, focusing on the current trends, market dynamics, and future prospects. The report explores the global Liposomes Nanocarrier Drug market, including major regions such as North America, Europe, Asia-Pacific, and emerging markets. It also examines key factors driving the growth of Liposomes Nanocarrier Drug, challenges faced by the industry, and potential opportunities for market players.
The global Liposomes Nanocarrier Drug market has witnessed rapid growth in recent years, driven by increasing environmental concerns, government incentives, and advancements in technology. The Liposomes Nanocarrier Drug market presents opportunities for various stakeholders, including Hospital, Retail Pharmacy. Collaboration between the private sector and governments can accelerate the development of supportive policies, research and development efforts, and investment in Liposomes Nanocarrier Drug market. Additionally, the growing consumer demand present avenues for market expansion.
The global Liposomes Nanocarrier Drug market was valued at US$ 4575.4 million in 2022 and is projected to reach US$ 10580 million by 2029, at a CAGR of 12.8% during the forecast period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Key Features:
The research report on the Liposomes Nanocarrier Drug market includes several key features to provide comprehensive insights and facilitate decision-making for stakeholders.
Executive Summary: The report provides overview of the key findings, market trends, and major insights of the Liposomes Nanocarrier Drug market.
Market Overview: The report provides a comprehensive overview of the Liposomes Nanocarrier Drug market, including its definition, historical development, and current market size. It covers market segmentation by Type (e.g., Liposomes Drugs, Lipid Nanoparticle Drugs), region, and application, highlighting the key drivers, challenges, and opportunities within each segment.
Market Dynamics: The report analyses the market dynamics driving the growth and development of the Liposomes Nanocarrier Drug market. The report includes an assessment of government policies and regulations, technological advancements, consumer trends and preferences, infrastructure development, and industry collaborations. This analysis helps stakeholders understand the factors influencing the Liposomes Nanocarrier Drug market’s trajectory.
Competitive Landscape: The report provides an in-depth analysis of the competitive landscape within the Liposomes Nanocarrier Drug market. It includes profiles of major market players, their market share, strategies, product portfolios, and recent developments.
Market Segmentation and Forecast: The report segment the Liposomes Nanocarrier Drug market based on various parameters, such as by Type, region, and by Application. It provides market size and growth forecasts for each segment, supported by quantitative data and analysis. This helps stakeholders identify growth opportunities and make informed investment decisions.
Technological Trends: The report should highlight the key technological trends shaping the Liposomes Nanocarrier Drug market, such as advancements in Type One technology and emerging substitutes. It analyses the impact of these trends on market growth, adoption rates, and consumer preferences.
Market Challenges and Opportunities: The report identify and analyses the major challenges faced by the Liposomes Nanocarrier Drug market, such as technical bottleneck, cost limitations, and high entry barrier. It also highlights the opportunities for market growth, such as government incentives, emerging markets, and collaborations between stakeholders.
Regulatory and Policy Analysis: The report should assess the regulatory and policy landscape for Liposomes Nanocarrier Drug, including government incentives, emission standards, and infrastructure development plans. It should analyse the impact of these policies on market growth and provide insights into future regulatory developments.
Recommendations and Conclusion: The report conclude with actionable recommendations for stakeholders, such as Application One Consumer, policymakers, investors, and infrastructure providers. These recommendations should be based on the research findings and address key challenges and opportunities within the Liposomes Nanocarrier Drug market.
Supporting Data and Appendices: The report include supporting data, charts, and graphs to substantiate the analysis and findings. It also includes appendices with additional detailed information, such as data sources, survey questionnaires, and detailed market forecasts.
Market Segmentation
Liposomes Nanocarrier Drug market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Liposomes Drugs
Lipid Nanoparticle Drugs
Market segment by Application
Hospital
Retail Pharmacy
Other
Global Liposomes Nanocarrier Drug Market Segment Percentages, By Region and Country, 2022 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Major players covered
Johnson & Johnson
Sun Pharmaceutical
CSPC
Kinyond
Teva
Fudan-Zhangjiang
Zydus Cadila
TTY Biopharma
Pacira
Luye Pharma
Leadiant Biosciences
Ipsen
Sayre Therapeutics
Jazz
Alnylam
Bausch Health
Acrotech Biopharma
Takeda
Chiesi Farmaceutici
Gilead Sciences
Outline of Major Chapters:
Chapter 1: Introduces the definition of Liposomes Nanocarrier Drug, market overview.
Chapter 2: Global Liposomes Nanocarrier Drug market size in revenue.
Chapter 3: Detailed analysis of Liposomes Nanocarrier Drug company competitive landscape, revenue and market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Liposomes Nanocarrier Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 8: The main points and conclusions of the report.
1 Introduction to Research & Analysis Reports
1.1 Liposomes Nanocarrier Drug Market Definition
1.2 Market Segments
1.2.1 Market by Type
1.2.2 Market by Application
1.3 Global Liposomes Nanocarrier Drug Market Overview
1.4 Features & Benefits of This Report
1.5 Methodology & Sources of Information
1.5.1 Research Methodology
1.5.2 Research Process
1.5.3 Base Year
1.5.4 Report Assumptions & Caveats
2 Global Liposomes Nanocarrier Drug Overall Market Size
2.1 Global Liposomes Nanocarrier Drug Market Size: 2022 VS 2029
2.2 Global Liposomes Nanocarrier Drug Market Size, Prospects & Forecasts: 2018-2029
2.3 Key Market Trends, Opportunity, Drivers and Restraints
2.3.1 Market Opportunities & Trends
2.3.2 Market Drivers
2.3.3 Market Restraints
3 Company Landscape
3.1 Top Liposomes Nanocarrier Drug Players in Global Market
3.2 Top Global Liposomes Nanocarrier Drug Companies Ranked by Revenue
3.3 Global Liposomes Nanocarrier Drug Revenue by Companies
3.4 Top 3 and Top 5 Liposomes Nanocarrier Drug Companies in Global Market, by Revenue in 2022
3.5 Global Companies Liposomes Nanocarrier Drug Product Type
3.6 Tier 1, Tier 2 and Tier 3 Liposomes Nanocarrier Drug Players in Global Market
3.6.1 List of Global Tier 1 Liposomes Nanocarrier Drug Companies
3.6.2 List of Global Tier 2 and Tier 3 Liposomes Nanocarrier Drug Companies
4 Market Sights by Product
4.1 Overview
4.1.1 By Type – Global Liposomes Nanocarrier Drug Market Size Markets, 2022 & 2029
4.1.2 Liposomes Drugs
4.1.3 Lipid Nanoparticle Drugs
4.2 By Type – Global Liposomes Nanocarrier Drug Revenue & Forecasts
4.2.1 By Type – Global Liposomes Nanocarrier Drug Revenue, 2018-2023
4.2.2 By Type – Global Liposomes Nanocarrier Drug Revenue, 2024-2029
4.2.3 By Type – Global Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
5 Sights by Application
5.1 Overview
5.1.1 By Application – Global Liposomes Nanocarrier Drug Market Size, 2022 & 2029
5.1.2 Hospital
5.1.3 Retail Pharmacy
5.1.4 Other
5.2 By Application – Global Liposomes Nanocarrier Drug Revenue & Forecasts
5.2.1 By Application – Global Liposomes Nanocarrier Drug Revenue, 2018-2023
5.2.2 By Application – Global Liposomes Nanocarrier Drug Revenue, 2024-2029
5.2.3 By Application – Global Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
6 Sights by Region
6.1 By Region – Global Liposomes Nanocarrier Drug Market Size, 2022 & 2029
6.2 By Region – Global Liposomes Nanocarrier Drug Revenue & Forecasts
6.2.1 By Region – Global Liposomes Nanocarrier Drug Revenue, 2018-2023
6.2.2 By Region – Global Liposomes Nanocarrier Drug Revenue, 2024-2029
6.2.3 By Region – Global Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
6.3 North America
6.3.1 By Country – North America Liposomes Nanocarrier Drug Revenue, 2018-2029
6.3.2 US Liposomes Nanocarrier Drug Market Size, 2018-2029
6.3.3 Canada Liposomes Nanocarrier Drug Market Size, 2018-2029
6.3.4 Mexico Liposomes Nanocarrier Drug Market Size, 2018-2029
6.4 Europe
6.4.1 By Country – Europe Liposomes Nanocarrier Drug Revenue, 2018-2029
6.4.2 Germany Liposomes Nanocarrier Drug Market Size, 2018-2029
6.4.3 France Liposomes Nanocarrier Drug Market Size, 2018-2029
6.4.4 U.K. Liposomes Nanocarrier Drug Market Size, 2018-2029
6.4.5 Italy Liposomes Nanocarrier Drug Market Size, 2018-2029
6.4.6 Russia Liposomes Nanocarrier Drug Market Size, 2018-2029
6.4.7 Nordic Countries Liposomes Nanocarrier Drug Market Size, 2018-2029
6.4.8 Benelux Liposomes Nanocarrier Drug Market Size, 2018-2029
6.5 Asia
6.5.1 By Region – Asia Liposomes Nanocarrier Drug Revenue, 2018-2029
6.5.2 China Liposomes Nanocarrier Drug Market Size, 2018-2029
6.5.3 Japan Liposomes Nanocarrier Drug Market Size, 2018-2029
6.5.4 South Korea Liposomes Nanocarrier Drug Market Size, 2018-2029
6.5.5 Southeast Asia Liposomes Nanocarrier Drug Market Size, 2018-2029
6.5.6 India Liposomes Nanocarrier Drug Market Size, 2018-2029
6.6 South America
6.6.1 By Country – South America Liposomes Nanocarrier Drug Revenue, 2018-2029
6.6.2 Brazil Liposomes Nanocarrier Drug Market Size, 2018-2029
6.6.3 Argentina Liposomes Nanocarrier Drug Market Size, 2018-2029
6.7 Middle East & Africa
6.7.1 By Country – Middle East & Africa Liposomes Nanocarrier Drug Revenue, 2018-2029
6.7.2 Turkey Liposomes Nanocarrier Drug Market Size, 2018-2029
6.7.3 Israel Liposomes Nanocarrier Drug Market Size, 2018-2029
6.7.4 Saudi Arabia Liposomes Nanocarrier Drug Market Size, 2018-2029
6.7.5 UAE Liposomes Nanocarrier Drug Market Size, 2018-2029
7 Liposomes Nanocarrier Drug Companies Profiles
7.1 Johnson & Johnson
7.1.1 Johnson & Johnson Company Summary
7.1.2 Johnson & Johnson Business Overview
7.1.3 Johnson & Johnson Liposomes Nanocarrier Drug Major Product Offerings
7.1.4 Johnson & Johnson Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.1.5 Johnson & Johnson Key News & Latest Developments
7.2 Sun Pharmaceutical
7.2.1 Sun Pharmaceutical Company Summary
7.2.2 Sun Pharmaceutical Business Overview
7.2.3 Sun Pharmaceutical Liposomes Nanocarrier Drug Major Product Offerings
7.2.4 Sun Pharmaceutical Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.2.5 Sun Pharmaceutical Key News & Latest Developments
7.3 CSPC
7.3.1 CSPC Company Summary
7.3.2 CSPC Business Overview
7.3.3 CSPC Liposomes Nanocarrier Drug Major Product Offerings
7.3.4 CSPC Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.3.5 CSPC Key News & Latest Developments
7.4 Kinyond
7.4.1 Kinyond Company Summary
7.4.2 Kinyond Business Overview
7.4.3 Kinyond Liposomes Nanocarrier Drug Major Product Offerings
7.4.4 Kinyond Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.4.5 Kinyond Key News & Latest Developments
7.5 Teva
7.5.1 Teva Company Summary
7.5.2 Teva Business Overview
7.5.3 Teva Liposomes Nanocarrier Drug Major Product Offerings
7.5.4 Teva Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.5.5 Teva Key News & Latest Developments
7.6 Fudan-Zhangjiang
7.6.1 Fudan-Zhangjiang Company Summary
7.6.2 Fudan-Zhangjiang Business Overview
7.6.3 Fudan-Zhangjiang Liposomes Nanocarrier Drug Major Product Offerings
7.6.4 Fudan-Zhangjiang Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.6.5 Fudan-Zhangjiang Key News & Latest Developments
7.7 Zydus Cadila
7.7.1 Zydus Cadila Company Summary
7.7.2 Zydus Cadila Business Overview
7.7.3 Zydus Cadila Liposomes Nanocarrier Drug Major Product Offerings
7.7.4 Zydus Cadila Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.7.5 Zydus Cadila Key News & Latest Developments
7.8 TTY Biopharma
7.8.1 TTY Biopharma Company Summary
7.8.2 TTY Biopharma Business Overview
7.8.3 TTY Biopharma Liposomes Nanocarrier Drug Major Product Offerings
7.8.4 TTY Biopharma Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.8.5 TTY Biopharma Key News & Latest Developments
7.9 Pacira
7.9.1 Pacira Company Summary
7.9.2 Pacira Business Overview
7.9.3 Pacira Liposomes Nanocarrier Drug Major Product Offerings
7.9.4 Pacira Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.9.5 Pacira Key News & Latest Developments
7.10 Luye Pharma
7.10.1 Luye Pharma Company Summary
7.10.2 Luye Pharma Business Overview
7.10.3 Luye Pharma Liposomes Nanocarrier Drug Major Product Offerings
7.10.4 Luye Pharma Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.10.5 Luye Pharma Key News & Latest Developments
7.11 Leadiant Biosciences
7.11.1 Leadiant Biosciences Company Summary
7.11.2 Leadiant Biosciences Business Overview
7.11.3 Leadiant Biosciences Liposomes Nanocarrier Drug Major Product Offerings
7.11.4 Leadiant Biosciences Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.11.5 Leadiant Biosciences Key News & Latest Developments
7.12 Ipsen
7.12.1 Ipsen Company Summary
7.12.2 Ipsen Business Overview
7.12.3 Ipsen Liposomes Nanocarrier Drug Major Product Offerings
7.12.4 Ipsen Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.12.5 Ipsen Key News & Latest Developments
7.13 Sayre Therapeutics
7.13.1 Sayre Therapeutics Company Summary
7.13.2 Sayre Therapeutics Business Overview
7.13.3 Sayre Therapeutics Liposomes Nanocarrier Drug Major Product Offerings
7.13.4 Sayre Therapeutics Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.13.5 Sayre Therapeutics Key News & Latest Developments
7.14 Jazz
7.14.1 Jazz Company Summary
7.14.2 Jazz Business Overview
7.14.3 Jazz Liposomes Nanocarrier Drug Major Product Offerings
7.14.4 Jazz Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.14.5 Jazz Key News & Latest Developments
7.15 Alnylam
7.15.1 Alnylam Company Summary
7.15.2 Alnylam Business Overview
7.15.3 Alnylam Liposomes Nanocarrier Drug Major Product Offerings
7.15.4 Alnylam Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.15.5 Alnylam Key News & Latest Developments
7.16 Bausch Health
7.16.1 Bausch Health Company Summary
7.16.2 Bausch Health Business Overview
7.16.3 Bausch Health Liposomes Nanocarrier Drug Major Product Offerings
7.16.4 Bausch Health Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.16.5 Bausch Health Key News & Latest Developments
7.17 Acrotech Biopharma
7.17.1 Acrotech Biopharma Company Summary
7.17.2 Acrotech Biopharma Business Overview
7.17.3 Acrotech Biopharma Liposomes Nanocarrier Drug Major Product Offerings
7.17.4 Acrotech Biopharma Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.17.5 Acrotech Biopharma Key News & Latest Developments
7.18 Takeda
7.18.1 Takeda Company Summary
7.18.2 Takeda Business Overview
7.18.3 Takeda Liposomes Nanocarrier Drug Major Product Offerings
7.18.4 Takeda Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.18.5 Takeda Key News & Latest Developments
7.19 Chiesi Farmaceutici
7.19.1 Chiesi Farmaceutici Company Summary
7.19.2 Chiesi Farmaceutici Business Overview
7.19.3 Chiesi Farmaceutici Liposomes Nanocarrier Drug Major Product Offerings
7.19.4 Chiesi Farmaceutici Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.19.5 Chiesi Farmaceutici Key News & Latest Developments
7.20 Gilead Sciences
7.20.1 Gilead Sciences Company Summary
7.20.2 Gilead Sciences Business Overview
7.20.3 Gilead Sciences Liposomes Nanocarrier Drug Major Product Offerings
7.20.4 Gilead Sciences Liposomes Nanocarrier Drug Revenue in Global Market (2018-2023)
7.20.5 Gilead Sciences Key News & Latest Developments
8 Conclusion
9 Appendix
9.1 Note
9.2 Examples of Clients
9.3 Disclaimer
Table 1. Liposomes Nanocarrier Drug Market Opportunities & Trends in Global Market
Table 2. Liposomes Nanocarrier Drug Market Drivers in Global Market
Table 3. Liposomes Nanocarrier Drug Market Restraints in Global Market
Table 4. Key Players of Liposomes Nanocarrier Drug in Global Market
Table 5. Top Liposomes Nanocarrier Drug Players in Global Market, Ranking by Revenue (2022)
Table 6. Global Liposomes Nanocarrier Drug Revenue by Companies, (US$, Mn), 2018-2023
Table 7. Global Liposomes Nanocarrier Drug Revenue Share by Companies, 2018-2023
Table 8. Global Companies Liposomes Nanocarrier Drug Product Type
Table 9. List of Global Tier 1 Liposomes Nanocarrier Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 10. List of Global Tier 2 and Tier 3 Liposomes Nanocarrier Drug Companies, Revenue (US$, Mn) in 2022 and Market Share
Table 11. By Type – Global Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2022 & 2029
Table 12. By Type - Liposomes Nanocarrier Drug Revenue in Global (US$, Mn), 2018-2023
Table 13. By Type - Liposomes Nanocarrier Drug Revenue in Global (US$, Mn), 2024-2029
Table 14. By Application – Global Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2022 & 2029
Table 15. By Application - Liposomes Nanocarrier Drug Revenue in Global (US$, Mn), 2018-2023
Table 16. By Application - Liposomes Nanocarrier Drug Revenue in Global (US$, Mn), 2024-2029
Table 17. By Region – Global Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2022 & 2029
Table 18. By Region - Global Liposomes Nanocarrier Drug Revenue (US$, Mn), 2018-2023
Table 19. By Region - Global Liposomes Nanocarrier Drug Revenue (US$, Mn), 2024-2029
Table 20. By Country - North America Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2023
Table 21. By Country - North America Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2024-2029
Table 22. By Country - Europe Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2023
Table 23. By Country - Europe Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2024-2029
Table 24. By Region - Asia Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2023
Table 25. By Region - Asia Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2024-2029
Table 26. By Country - South America Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2023
Table 27. By Country - South America Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2024-2029
Table 28. By Country - Middle East & Africa Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2023
Table 29. By Country - Middle East & Africa Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2024-2029
Table 30. Johnson & Johnson Company Summary
Table 31. Johnson & Johnson Liposomes Nanocarrier Drug Product Offerings
Table 32. Johnson & Johnson Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 33. Johnson & Johnson Key News & Latest Developments
Table 34. Sun Pharmaceutical Company Summary
Table 35. Sun Pharmaceutical Liposomes Nanocarrier Drug Product Offerings
Table 36. Sun Pharmaceutical Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 37. Sun Pharmaceutical Key News & Latest Developments
Table 38. CSPC Company Summary
Table 39. CSPC Liposomes Nanocarrier Drug Product Offerings
Table 40. CSPC Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 41. CSPC Key News & Latest Developments
Table 42. Kinyond Company Summary
Table 43. Kinyond Liposomes Nanocarrier Drug Product Offerings
Table 44. Kinyond Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 45. Kinyond Key News & Latest Developments
Table 46. Teva Company Summary
Table 47. Teva Liposomes Nanocarrier Drug Product Offerings
Table 48. Teva Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 49. Teva Key News & Latest Developments
Table 50. Fudan-Zhangjiang Company Summary
Table 51. Fudan-Zhangjiang Liposomes Nanocarrier Drug Product Offerings
Table 52. Fudan-Zhangjiang Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 53. Fudan-Zhangjiang Key News & Latest Developments
Table 54. Zydus Cadila Company Summary
Table 55. Zydus Cadila Liposomes Nanocarrier Drug Product Offerings
Table 56. Zydus Cadila Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 57. Zydus Cadila Key News & Latest Developments
Table 58. TTY Biopharma Company Summary
Table 59. TTY Biopharma Liposomes Nanocarrier Drug Product Offerings
Table 60. TTY Biopharma Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 61. TTY Biopharma Key News & Latest Developments
Table 62. Pacira Company Summary
Table 63. Pacira Liposomes Nanocarrier Drug Product Offerings
Table 64. Pacira Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 65. Pacira Key News & Latest Developments
Table 66. Luye Pharma Company Summary
Table 67. Luye Pharma Liposomes Nanocarrier Drug Product Offerings
Table 68. Luye Pharma Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 69. Luye Pharma Key News & Latest Developments
Table 70. Leadiant Biosciences Company Summary
Table 71. Leadiant Biosciences Liposomes Nanocarrier Drug Product Offerings
Table 72. Leadiant Biosciences Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 73. Leadiant Biosciences Key News & Latest Developments
Table 74. Ipsen Company Summary
Table 75. Ipsen Liposomes Nanocarrier Drug Product Offerings
Table 76. Ipsen Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 77. Ipsen Key News & Latest Developments
Table 78. Sayre Therapeutics Company Summary
Table 79. Sayre Therapeutics Liposomes Nanocarrier Drug Product Offerings
Table 80. Sayre Therapeutics Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 81. Sayre Therapeutics Key News & Latest Developments
Table 82. Jazz Company Summary
Table 83. Jazz Liposomes Nanocarrier Drug Product Offerings
Table 84. Jazz Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 85. Jazz Key News & Latest Developments
Table 86. Alnylam Company Summary
Table 87. Alnylam Liposomes Nanocarrier Drug Product Offerings
Table 88. Alnylam Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 89. Alnylam Key News & Latest Developments
Table 90. Bausch Health Company Summary
Table 91. Bausch Health Liposomes Nanocarrier Drug Product Offerings
Table 92. Bausch Health Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 93. Bausch Health Key News & Latest Developments
Table 94. Acrotech Biopharma Company Summary
Table 95. Acrotech Biopharma Liposomes Nanocarrier Drug Product Offerings
Table 96. Acrotech Biopharma Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 97. Acrotech Biopharma Key News & Latest Developments
Table 98. Takeda Company Summary
Table 99. Takeda Liposomes Nanocarrier Drug Product Offerings
Table 100. Takeda Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 101. Takeda Key News & Latest Developments
Table 102. Chiesi Farmaceutici Company Summary
Table 103. Chiesi Farmaceutici Liposomes Nanocarrier Drug Product Offerings
Table 104. Chiesi Farmaceutici Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 105. Chiesi Farmaceutici Key News & Latest Developments
Table 106. Gilead Sciences Company Summary
Table 107. Gilead Sciences Liposomes Nanocarrier Drug Product Offerings
Table 108. Gilead Sciences Liposomes Nanocarrier Drug Revenue (US$, Mn) & (2018-2023)
Table 109. Gilead Sciences Key News & Latest Developments
List of Figures
Figure 1. Liposomes Nanocarrier Drug Segment by Type in 2022
Figure 2. Liposomes Nanocarrier Drug Segment by Application in 2022
Figure 3. Global Liposomes Nanocarrier Drug Market Overview: 2022
Figure 4. Key Caveats
Figure 5. Global Liposomes Nanocarrier Drug Market Size: 2022 VS 2029 (US$, Mn)
Figure 6. Global Liposomes Nanocarrier Drug Revenue, 2018-2029 (US$, Mn)
Figure 7. The Top 3 and 5 Players Market Share by Liposomes Nanocarrier Drug Revenue in 2022
Figure 8. By Type - Global Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 9. By Application - Global Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 10. By Type - Global Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2022 & 2029
Figure 11. By Type - Global Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 12. By Application - Global Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2022 & 2029
Figure 13. By Application - Global Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 14. By Region - Global Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 15. By Country - North America Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 16. US Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 17. Canada Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 18. Mexico Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 19. By Country - Europe Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 20. Germany Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 21. France Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 22. U.K. Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 23. Italy Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 24. Russia Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 25. Nordic Countries Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 26. Benelux Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 27. By Region - Asia Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 28. China Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 29. Japan Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 30. South Korea Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 31. Southeast Asia Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 32. India Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 33. By Country - South America Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 34. Brazil Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 35. Argentina Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 36. By Country - Middle East & Africa Liposomes Nanocarrier Drug Revenue Market Share, 2018-2029
Figure 37. Turkey Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 38. Israel Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 39. Saudi Arabia Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 40. UAE Liposomes Nanocarrier Drug Revenue, (US$, Mn), 2018-2029
Figure 41. Johnson & Johnson Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 42. Sun Pharmaceutical Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 43. CSPC Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 44. Kinyond Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 45. Teva Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 46. Fudan-Zhangjiang Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 47. Zydus Cadila Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 48. TTY Biopharma Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 49. Pacira Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 50. Luye Pharma Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 51. Leadiant Biosciences Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 52. Ipsen Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 53. Sayre Therapeutics Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 54. Jazz Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 55. Alnylam Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 56. Bausch Health Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 57. Acrotech Biopharma Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 58. Takeda Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 59. Chiesi Farmaceutici Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)
Figure 60. Gilead Sciences Liposomes Nanocarrier Drug Revenue Year Over Year Growth (US$, Mn) & (2018-2023)